Crawford Pharmaceuticals announces management buyout

Crawford Pharmaceuticals’ management has announced the completion of a successful buyout of the company.

In a statement issued yesterday, the company’s chief executive officer Richard Anderson said that the move provides Crawford with a “strong platform” that enables the firm with the opportunity to further establish itself as a “partner of choice” for those operating in the dermatology sector.

He said that the organisation will continue to listen and understand its partners’ needs in order to meet them.

The enterprise’s portfolio now includes a number of well-known brands, including Zindaclin, Sunsense and the Chemotechnique Patch Tests and the company asserted that it is one of the country’s leading suppliers of “specials” to the dermatology sector.

Other products include ViTiX skincare gel, a new product that is used for the management of depigmentation in conditions like Vitiligo, as well as Cuplex, a topical gel treatment designed for the treatment of verrucae and warts.